CCL2 and atherosclerosis: To further reveal the mechanisms of reducing atherosclerosis lesions by blocking TLR4/NF-κB, we investigated the effects of Ad-TLR4 siRNA and NF-κB antagonist PDTC on inflammatory cytokines such IL-1β, MCP-1, and TNF-α.